Next Phase Newsletter

A life sciences venture capital fund based in Hong Kong currently manages three funds and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The life science investment arm of a global private equity firm with multi-billion dollars in assets under management has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. The PE firm also has a separate investment arm that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.

The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.

The growth-stage investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, The firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in West Coast USA invests across all stages, from company formation through IPO. As an evergreen fund, the firm has invested in big name biotech companies, and is capable of making large investments with no set limit.

The firm is primarily focused on 3 areas: (1) therapeutics, (2) diagnostics, and (3) synthetic biology, but open to other sectors with groundbreaking technology.

The firm has a flexible mandate and does not have any specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA is actively seeking early-stage investment opportunities in life sciences and healthcare sectors with its first fund. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate a portion of their fund to invest outside of the USA.

The firm invests in 4 main focus areas, ordered by priority: (1) biotech, which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health, which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech, which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech, which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.

The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare, including AI in healthcare and medical devices. The firm typically invests $1-2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their extensive network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage fund based in Israel is investing in private companies developing pharmaceuticals only. The firm invests in early stage projects, preferably with PoC validation, and supports companies from venture creation to Series A. The firm’s average ticket size is $15M along the lifespan of the company and comes in the form of straight equity. The firm seeks board representation and is a very active investor, helping guide the company’s development and strategy. The firm is fundamentally science-driven, invests globally and may lead or co-invest. The firm has no targeted number of investments per year.

The firm’s mother company recently launched a late stage fund that seeks investments in private companies developing pharmaceuticals which raise Series B and up to Crossover round/IPO.

Both early-stage and late stage funds are open to both pre-clinical and clinical stage companies and are agnostic to technology type and indication. The firm has a specific interest in immuno-oncology, gene therapy, RNA/DNA based therapy and orphan or unmet medical need. The firm is only interested in first-in-class, breakthrough assets and does not consider re-purposed assets, diagnostics, medical devices or iterative technologies.

The firm prefers to invest early and help take the company through a major inflection point. The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm with offices in multiple cities throughout the USA recently closed its newest fund and is actively seeking new investment opportunities. The firm is focused on investing in Seed to Series A rounds, with initial check sizes ranging from $2-3M, and $5-10M reserved for follow-on investment. The firm invests in global opportunities.

The firm invests in a wide variety of industries, ranging from transportation, energy, infrastructure, manufacturing, agriculture, etc. The firm has a broad interest in life sciences and will consider opportunities in therapeutics, medical devices, diagnostics, and computationally enabled solutions, and is open to different types of modalities and indications. However, the firm does have a strong interest in human augmentation, which includes technologies dedicated to longevity and enhancing quality of life, cognition, enhancement, etc.

The firm’s management team is comprised of entrepreneurs who have been through the investment and fundraising process – the firm seeks companies run by driven entrepreneurs (open to both first-time and serial) whom they can work together based on mutual trust. The firm prefers to lead investment rounds and seek board representation, but is open to co-investing. The firm invests in a small number of companies and seeks to have a very active, hands-on role in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.